AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24326980 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 μM piperine
Number of subjects: 40
Study 24326980 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mM piperine
Number of subjects: 40
Study 22119244 — intervention group
Group type: EXPERIMENTAL
Intervention: K-134 50 mg
Number of subjects: 402
Study 22119244 — intervention group
Group type: EXPERIMENTAL
Intervention: K-134 100 mg
Number of subjects: 402
Study 22119244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg
Number of subjects: 402
Study 22119244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 22119244 — intervention group
Group type: EXPERIMENTAL
Intervention: K-134
Number of subjects: 402
Study 22119244 — intervention group
Group type: EXPERIMENTAL
Intervention: K-134 and cilostazol
Number of subjects: 402
Study 19221402 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (milked group, n = 20)
Number of subjects: 40
Study 19221402 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 17503880 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation drug-eluting stents (including sirolimus analogs, biodegradable and bioabsorbable materials)
Number of subjects: 0
Study 17503880 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoir stents with different drug release profiles
Number of subjects: 0
Study 15489844 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus tianeptine 37.5 mg/day
Number of subjects: 40
Study 15489844 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 40
Study 16123227 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (15 mg/week for 8 weeks)
Number of subjects: 23
Study 16123227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory Evoked Potential (AEP) index
Number of subjects: 46
Study 10364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 46
Study 10364994 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% Spectral Edge Frequency (SEF)
Number of subjects: 46
Study 10364994 — intervention group
Group type: EXPERIMENTAL
Intervention: Median Frequency (MF)
Number of subjects: 46
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat snack foods after low energy lunch
Number of subjects: 20
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat snack foods after high energy lunch
Number of subjects: 20
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose snack foods after low energy lunch
Number of subjects: 20
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose snack foods after high energy lunch
Number of subjects: 20
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy lunch followed by high sucrose snack
Number of subjects: 20
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat snacks
Number of subjects: 20
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: Test day energy intake excluding alcoholic drinks
Number of subjects: 20
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: Day following study day energy intake
Number of subjects: 20
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite ratings
Number of subjects: 20
Study 8880042 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat snacks pleasantness rating
Number of subjects: 20
Study 1994861 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 12
Study 1994861 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (Proton density and STIR sequences)
Number of subjects: 12
Study 6594713 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg naloxone
Number of subjects: 10
Study 6594713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31141497 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich salad and citrulline drink (520mg nitrate and 6g citrulline)
Number of subjects: 24
Study 31141497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 24
Study 27937084 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (REB) ophthalmic suspension
Number of subjects: 40
Study 27937084 — intervention group
Group type: COMPARATOR
Intervention: Diquafosol (DQS) ophthalmic solution
Number of subjects: 40
Study 26785125 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported rating of adherence
Number of subjects: 1147
Study 26785125 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported frequency of doses taken
Number of subjects: 1147
Study 26785125 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported percentage of doses taken
Number of subjects: 1147
Study 26785125 — intervention group
Group type: EXPERIMENTAL
Intervention: Unannounced pill counts (UPC)
Number of subjects: 1147
Study 26785125 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic monitoring
Number of subjects: 1147
Study 26785125 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma tenofovir levels (SSDD; ≥40 ng/ml)
Number of subjects: 1147
Study 26785125 — intervention group
Group type: COMPARATOR
Intervention: Self-reported rating
Number of subjects: 1147
Study 26785125 — intervention group
Group type: COMPARATOR
Intervention: Self-reported frequency
Number of subjects: 1147
Study 26785125 — intervention group
Group type: COMPARATOR
Intervention: Self-reported percentage
Number of subjects: 1147
Study 26785125 — intervention group
Group type: COMPARATOR
Intervention: Correlation among self-reported measures
Number of subjects: 1147
Study 26785125 — intervention group
Group type: COMPARATOR
Intervention: Correlation between self-reported measures and UPC
Number of subjects: 1147
Study 26785125 — intervention group
Group type: COMPARATOR
Intervention: Correlation between self-reported measures and electronic monitoring
Number of subjects: 1147
Study 24504688 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (7 mg) plus dimeticone (40 mg) and pepsin (50 mg)
Number of subjects: 0
Study 24504688 — intervention group
Group type: COMPARATOR
Intervention: Conventional metoclopramide capsule (7 mg)
Number of subjects: 0
Study 21750253 — intervention group
Group type: EXPERIMENTAL
Intervention: QUI (quinapril) 40 mg/d
Number of subjects: 40
Study 21750253 — intervention group
Group type: EXPERIMENTAL
Intervention: QUI + ALA (quinapril 40 mg/d + α-lipoic acid 600 mg/d)
Number of subjects: 40
Study 19218830 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 316
Study 19218830 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 316
Study 19218830 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation phase (nonrelapsing subjects)
Number of subjects: 316
Study 19218830 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation phase (relapsing subjects)
Number of subjects: 316
Study 19218830 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive component scores at entry into continuation
Number of subjects: 316
Study 17445589 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 35 mg/wk for 6 months (Group A)
Number of subjects: 50
Study 17445589 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 50
Study 16198251 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker
Number of subjects: 800
Study 12546524 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IE epoetin‐beta
Number of subjects: 180
Study 12546524 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IE epoetin‐beta
Number of subjects: 180
Study 12546524 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 180
Study 12546524 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measurement (EORTC QLQ‐C30)
Number of subjects: 180
Study 9803777 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet with hypercaloric supplement (Suplena)
Number of subjects: 33
Study 9803777 — intervention group
Group type: COMPARATOR
Intervention: Control group (same low-protein diet, 0.6 g protein/kg/day)
Number of subjects: 33
Study 7644095 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable staples in vaginal cuff closure
Number of subjects: 104
Study 7644095 — intervention group
Group type: COMPARATOR
Intervention: Classical abdominal hysterectomy
Number of subjects: 104
Study 30993795 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium abutment‐supported porcelain fused to metal (PFM) restorations
Number of subjects: 170
Study 30993795 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium abutment‐supported ceramic restorations
Number of subjects: 170
Study 30993795 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched in gender and age)
Number of subjects: 170
Study 28182279 — intervention group
Group type: EXPERIMENTAL
Intervention: AMIO + RAN (1 g oral dose)
Number of subjects: 173
Study 28182279 — intervention group
Group type: COMPARATOR
Intervention: AMIO (5 mg/kg loading dose followed by 50 mg/h)
Number of subjects: 173
Study 26731976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral waters, peloids, and calcipotriol
Number of subjects: 60
Study 26731976 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol alone
Number of subjects: 60
Study 23455699 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 69
Study 23455699 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined epidural and general anesthesia
Number of subjects: 69
Study 23455699 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal and general anesthesia
Number of subjects: 69
Study 21714757 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg) administered daily for four weeks
Number of subjects: 14
Study 21714757 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily for four weeks
Number of subjects: 14
Study 19781325 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxygenated solution (HO group, n = 109)
Number of subjects: 5
Study 19781325 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (NO group, n = 115)
Number of subjects: 5
Study 16475478 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Depressive Disorder (MDD) group
Number of subjects: 173
Study 16475478 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 173
Study 14559126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 87339
Study 11084156 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 0
Study 11084156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of hip protectors
Number of subjects: 0
Study 9392326 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon sampler
Number of subjects: 439
Study 9392326 — intervention group
Group type: EXPERIMENTAL
Intervention: Sponge sampler
Number of subjects: 439
Study 8513722 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 84
Study 8513722 — intervention group
Group type: COMPARATOR
Intervention: H2-blockers
Number of subjects: 84
Study 3541602 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (1 mg two times daily to maximum of 20 mg per day)
Number of subjects: 31
Study 3541602 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg three times daily to a maximum of 450 mg per day)
Number of subjects: 31
Study 3541602 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin + Polythiazide (if diastolic blood pressure not controlled)
Number of subjects: 31
Study 3541602 — intervention group
Group type: COMPARATOR
Intervention: Captopril + Polythiazide (if diastolic blood pressure not controlled)
Number of subjects: 31
Study 31593299 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL lidocaine 2% diluted in 15 mL normal saline
Number of subjects: 260
Study 31593299 — intervention group
Group type: COMPARATOR
Intervention: 20 mL normal saline alone
Number of subjects: 260
Study 30602688 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (5-6 targets met)
Number of subjects: 874
Study 27649232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention combined with health education
Number of subjects: 0
Study 27649232 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 0
Study 24912663 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Number of subjects: 41
Study 24912663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 22034645 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 40
Study 22034645 — intervention group
Group type: COMPARATOR
Intervention: Prudent diet (PD)
Number of subjects: 40
Study 20386132 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline malate (CM) 8 grams
Number of subjects: 41
Study 20386132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 19293592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade with ACE inhibitor and angiotensin II receptor blocker
Number of subjects: 93
Study 19293592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dual blockade)
Number of subjects: 93
Study 16437672 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g twice a day)
Number of subjects: 150
Study 16437672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 12608523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional weight loss (IWL)
Number of subjects: 0
Study 12608523 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically recommended methods for IWL
Number of subjects: 0
Study 10496437 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 8 mg once daily
Number of subjects: 217
Study 10496437 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil 16 mg once daily
Number of subjects: 217
Study 10496437 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 217
Study 10496437 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil
Number of subjects: 217
Study 8545570 — intervention group
Group type: EXPERIMENTAL
Intervention: Photocoagulation
Number of subjects: 1058
Study 8545570 — intervention group
Group type: COMPARATOR
Intervention: Baseline accommodative amplitude
Number of subjects: 1058
Study 1721575 — intervention group
Group type: EXPERIMENTAL
Intervention: Arithmetic task
Number of subjects: 0
Study 1721575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rotation task
Number of subjects: 0
Study 7129643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 60
Study 7129643 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 60
Study 31699069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE) combined with rehabilitation
Number of subjects: 119
Study 31699069 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation only (control group)
Number of subjects: 119
Study 30588956 — intervention group
Group type: EXPERIMENTAL
Intervention: Advagraf (once-daily tacrolimus)
Number of subjects: 99
Study 30588956 — intervention group
Group type: COMPARATOR
Intervention: Prograf (twice-daily tacrolimus)
Number of subjects: 99
Study 26767411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (SC) 50 mg capsules, maximum 150 mg, given eight hourly during labour
Number of subjects: 100
Study 26767411 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules given eight hourly during labour
Number of subjects: 100
Study 24694207 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management education for epilepsy (SMILE (UK) course with treatment as usual)
Number of subjects: 428
Study 24694207 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 428
Study 22316315 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal gel containing isoflavones, Lactobacillus sporogenes, Calendula officinalis extract and lactic acid (Estromineral Gel, Rottapharm‐Madaus) for 4 weeks, plus daily oral isoflavones and L. sporogenes.
Number of subjects: 186
Study 22316315 — intervention group
Group type: COMPARATOR
Intervention: No topical treatment (NT) for 4 weeks, plus daily oral isoflavones and L. sporogenes.
Number of subjects: 186
Study 20807792 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mm capsazepine
Number of subjects: 10
Study 20807792 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mm l‐NAME
Number of subjects: 10
Study 20807792 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 20 mm capsazepine + 10 mm l‐NAME
Number of subjects: 10
Study 20807792 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (90% propylene glycol + 10% lactated Ringer solution)
Number of subjects: 10
Study 16097707 — intervention group
Group type: COMPARATOR
Intervention: antibacterial therapy
Number of subjects: 69
Study 16097707 — intervention group
Group type: COMPARATOR
Intervention: antibacterial therapy + alpha-adrenoblockers
Number of subjects: 69
Study 16097707 — intervention group
Group type: EXPERIMENTAL
Intervention: antibacterial therapy + transrectal laser and magnetic physiotherapy
Number of subjects: 69
Study 16097707 — intervention group
Group type: EXPERIMENTAL
Intervention: antibacterial therapy + alpha-adrenoblockers + transrectal laser and magnetic physiotherapy
Number of subjects: 69
Study 11849155 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic human tumour cell vaccine with Mycobacterium vaccae (SRL‐172)
Number of subjects: 60
Study 11849155 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 10399410 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer (RMGI) - Vitremer
Number of subjects: 2
Study 10399410 — intervention group
Group type: COMPARATOR
Intervention: Silver-reinforced glass ionomer (cermet) - Ketac-Silver
Number of subjects: 2
Study 7581527 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus recombinant alpha-interferon 2b
Number of subjects: 36
Study 7581527 — intervention group
Group type: COMPARATOR
Intervention: BCG full dose
Number of subjects: 36
Study 2184287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (5 mg/kg over 20 minutes)
Number of subjects: 80
Study 2184287 — intervention group
Group type: COMPARATOR
Intervention: Oral quinidine (400 mg immediately and 400 mg in 4 hours)
Number of subjects: 80
Study 2184287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 80
Study 2184287 — intervention group
Group type: COMPARATOR
Intervention: Oral quinidine
Number of subjects: 80
Study 6115246 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) (200 mg/day)
Number of subjects: 40
Study 6115246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (2 g/day)
Number of subjects: 40
Study 6115246 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg per week)
Number of subjects: 40
Study 6115246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole plus Levamisole
Number of subjects: 40
Study 28917678 — intervention group
Group type: EXPERIMENTAL
Intervention: OFDI-guided PCI
Number of subjects: 106
Study 28917678 — intervention group
Group type: COMPARATOR
Intervention: IVUS-guided PCI
Number of subjects: 106
Study 27191247 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of red grape seed extract (RGSE) for eight weeks
Number of subjects: 70
Study 27191247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24723314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological blockade of α‐adrenergic‐, muscarinic‐, and calcium channel‐mediated mechanisms
Number of subjects: 43
Study 24355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access to chest CT before chest-physician evaluation
Number of subjects: 493
Study 24355447 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard pathway)
Number of subjects: 493
Study 24355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct access to chest CT
Number of subjects: 493
Study 21208095 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT and protein-enriched enteral nutrition (Group I)
Number of subjects: 229
Study 21208095 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric enteral nutrition (Group II)
Number of subjects: 229
Study 18030411 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative multidisciplinary, multifactorial fall-prevention program including staff education, systematic assessment and treatment of fall risk factors, vitamin D and calcium supplementation
Number of subjects: 199
Study 18030411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 199
Study 18030411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 199
Study 18030411 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study 16816303 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone or Haloperidol (flexible dose, median treatment length 206 days)
Number of subjects: 530
Study 12816293 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal-based mouthrinse with oral irrigator
Number of subjects: 89
Study 12816293 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional mouthwash with oral irrigator
Number of subjects: 89
Study 12816293 — intervention group
Group type: COMPARATOR
Intervention: Conventional mouthwash without subgingival irrigation
Number of subjects: 89
Study 10854652 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta1a (Avonex)
Number of subjects: 0
Study 9120313 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant envelope proteins (Env, gp120, and gp160)
Number of subjects: 0
Study 9120313 — intervention group
Group type: EXPERIMENTAL
Intervention: Live virus or recombinant protein immunogen
Number of subjects: 0
Study 1555906 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 31
Study 1555906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3890538 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 74